The US Food and Drug Administration (FDA) is investigating a potential risk of tumour formation associated with Zolgensma and Itvisma gene therapies for spinal muscular atrophy (SMA), following evidence of viral vector DNA integration into patients' genomes.
Babies with the most severe form of SMA experience progressive muscle weakness, paralysis, and difficulty breathing. Without treatment, their life expectancy is around two years. Zolgensma is administered as a one-time intravenous infusion, and uses an adeno-associated virus (AAV) vector to deliver a functional copy of the SMN1 gene to cells. The investigation follows reports of tumours in treated patients, with molecular analysis identifying evidence of the viral vector integrating into patients' DNA in two cases. The FDA is also assessing the potential risk associated with Itvisma, another SMA gene therapy that uses the same viral vector and genetic construct. No cases of tumour formation have been reported following Itvisma treatment.
The FDA stated in a safety communication that 'the overall benefits of Zolgensma and Itvisma continue to outweigh their potential risks for their approved uses,' but said it was investigating the safety signal and assessing whether regulatory action was required.
SMA is a degenerative genetic condition affecting motor neurons, the nerve cells that control voluntary muscle movement. Faulty copies of the SMN1 gene mean that motor neurons lack sufficient SMN protein and progressively die, causing muscle weakness and wasting that can affect movement, breathing and swallowing. Around one in 40 people in the UK carry a faulty copy of the SMN1 gene, but the condition only develops in people who inherit two non-functional copies. Around 65 babies are born with SMA in the UK each year, and without treatment, most of those with the severe form of the condition die in infancy.
Zolgensma was first approved in the USA in May 2019, and approved for use by the NHS in March 2021 (see BioNews 1321, 1098 and 1087). Since then, over 6000 patients have received the therapy, and nine reports of tumour formation in treated patients have been received by its manufacturer, Novartis. These include tumours affecting the central and peripheral nervous systems, spinal and paraspinal regions, and kidneys.
Three cases involved tumours associated with GLI1, a gene that can contribute to cancer development when abnormally activated or overexpressed. In two of these cases, analysis of tumour tissue demonstrated that DNA from the AAV vector used in Zolgensma had integrated into the patients' genomes, near or within the GLI1 gene. The mechanism behind GLI1 overexpression in the third case remains under investigation.
Although AAV vectors are generally considered to have a low risk of integration, AAV gene therapy vector DNA has previously been found integrated within tumour tissue in a patient with Hurler syndrome who had been treated years earlier with a different gene therapy as part of a clinical trial (see BioNews 1340). A further case involving a patient with Krabbe disease who developed a tumour following investigational AAV gene therapy has also been highlighted by the FDA.
Novartis, the manufacturer, is conducting long-term follow-up studies, and the FDA has advised that patients receiving the treatments should be monitored for tumour formation.

